Quick Answer
Spermidine supplements (most often wheat-germ extracts) have a strong mechanistic rationale for cellular “housekeeping” pathways, including autophagy signaling (Madeo et al., 2018). In humans, a short pilot trial showed a promising memory signal, whereas a longer 12-month trial did not improve the primary memory outcome but confirmed good safety and suggested possible responder signals (Wirth et al., 2018; Schwarz et al., 2022). (Science)
By Superfood Science Writing Team | Evidence-Informed | Updated 2026
Key Takeaways
- Spermidine supplements have a credible “why” and an excellent safety/tolerability profile in older adults in published trials (Schwarz et al., 2018; Schwarz et al., 2022). (Aging-US)
- A 3-month pilot trial in subjective cognitive decline reported moderate effect-size improvements in memory measures—promising, not definitive (Wirth et al., 2018). (PubMed)
- A 12-month RCT using 0.9 mg/day of spermidine from wheat-germ extract did not improve the primary memory outcome, but exploratory analyses suggested possible signals (e.g., inflammation/verbal memory), and the authors encouraged future trials at a higher dose (Schwarz et al., 2022). (PMC)
- Food-first remains foundational, but supplements may serve as a practical “consistency tool” for people who can’t reliably consume spermidine-rich foods (Muñoz-Esparza et al., 2021). (MDPI)
Why a “positive outlook” is still reasonable
If you read only headlines, “trial negative” sounds like “supplement useless.” The better interpretation is: we have a biologically plausible nutrient with early signals, good safety, and unresolved questions about dose, responders, and endpoints (Schwarz et al., 2022). (PMC)
That’s actually a common pattern in nutrition science: the first large RCT doesn’t always hit the primary endpoint, but it teaches us how to run the next, smarter trial (dose, target group, duration, biomarkers).
What the two key studies show
1) The safety/tolerability foundation (why this matters)
A 3-month randomized, placebo-controlled trial in older adults with subjective cognitive decline using a spermidine-rich wheat-germ extract reported no differences in safety labs, vital signs, or self-reported health, with high compliance supporting tolerability at studied doses (Schwarz et al., 2018). (Aging-US)
This is important because it supports a responsible next step: testing higher doses and longer duration under clinical monitoring (Schwarz et al., 2018; Schwarz et al., 2022). (Aging-US)
2) The longer 12-month RCT (what “no improvement” really means)
In the SmartAge phase 2b trial (100 participants, 12 months), the intervention was a wheat-germ extract providing 0.9 mg/day spermidine, and it did not improve the primary memory outcome (mnemonic discrimination) vs placebo (Schwarz et al., 2022). (PMC)
But two “positive outlook” details matter:
- The study had an excellent safety profile and balanced adverse events (Schwarz et al., 2022). (PMC)
- The authors report exploratory/per-protocol and subgroup signals (e.g., inflammation/verbal memory) and explicitly point to future trials with higher dosage (Schwarz et al., 2022). (JAMA Network)
Why didn’t the supplement work if foods seemed helpful?
First, a key clarification: the strongest “improved cognition” signal in this research line came from a supplement pilot trial, not from diet-only food trials (Wirth et al., 2018). (PubMed)
Still, it’s a fair question, why do we see signals in some contexts (diet associations or short trials) but not in a longer RCT?
Here are the most plausible reasons discussed or implied by the two studies, stated conservatively:
Reason 1: Dose and “delta” may have been too small
The 12-month trial increased daily spermidine supply by about 10%, which may be too small to affect cognitive endpoints in a heterogeneous older adult group (Schwarz et al., 2022). (JAMA Network)
Reason 2: Wrong population mix for a nutrition intervention
The SmartAge authors note that Alzheimer biomarkers (amyloid/tau) were not required, and amyloid status was available for only a subset—meaning many participants may not have had the biological subtype most likely to respond (Schwarz et al., 2022). (JAMA Network)
Reason 3: Duration might still be too short for cognition trajectories
Even 12 months may be too short to detect changes against the slow background of cognitive aging, and the authors discuss this as a limitation, while also noting that a shorter 3-month study showed signals of benefit (Schwarz et al., 2022; Wirth et al., 2018). (JAMA Network)
Reason 4: Blood levels may not reflect tissue uptake (so “no change” ≠ “no effect”)
In the safety/tolerability paper, spermidine supplementation did not robustly change whole-blood polyamines, and the authors discuss the possibility of rapid absorption/metabolism into solid tissues (Schwarz et al., 2018). (Aging-US)
Reason 5: “Food effects” may be lifestyle effects
Observational studies linking higher dietary spermidine intake to better outcomes can be confounded by overall diet quality and healthy behaviors (Kiechl et al., 2018). (PubMed)
So it’s possible that “foods looked better” partly because foods reflect a bigger, healthier pattern.
Reason 6: The Microbiome Factor
Our gut bacteria also produce spermidine, and individual differences in the microbiome may explain why some people respond more robustly to external supplements than others.
Clinical Note
If you want a positive, evidence-aligned approach, think of spermidine supplements as a consistency tool—not a cognitive “treatment.” If you’re aiming at brain aging outcomes, pair any supplement trial with the basics that reliably move the needle: resistance training, sleep regularity, cardiometabolic health, and nutrient-dense meals.
If you have active cancer treatment, complex medications, or are immuno-compromised, discuss supplements with your clinician first.
Practitioner-Recommended Usage Guide
Step 1: Decide whether you’re a “food-first” or “food + supplement” person.
Foods that commonly contribute meaningful spermidine in surveys include wheat germ and mushrooms (Muñoz-Esparza et al., 2021). (MDPI)
Step 2: If you choose a supplement, choose the form that matches the trials.
The published cognition trials used formulations of spermidine-rich wheat germ extract (Schwarz et al., 2018; Schwarz et al., 2022; Wirth et al., 2018). (Aging-US)
Step 3: Track outcomes realistically for 8–12 weeks, not 8 days.
Use simple measures: sleep quality, energy, attention consistency, and (if you want) a brief cognitive task app—knowing that practice effects are real.
Step 4: Keep the “stack” clean.
If you start spermidine, avoid adding five other new supplements the same month. Otherwise, you won’t know what did.
Safety and Interactions
In published trials, spermidine-rich wheat-germ extract was generally well tolerated in older adults at studied doses (Schwarz et al., 2018; Schwarz et al., 2022). (Aging-US)
Practical cautions:
- If you have celiac disease or a wheat allergy, wheat germ extract products may not be suitable.
- If you are on complex medication regimens, pregnant/breastfeeding, or immunocompromised, check with a clinician.
Limitations and Research Gaps
We still need trials that test higher doses, longer durations, biomarker-defined subgroups, and outcomes beyond a single memory task (Schwarz et al., 2022). (PMC)
We also need better clarity on responders vs non-responders (microbiome, baseline spermidine intake, and metabolic status).
FAQ
Q: Did spermidine supplements “fail” for cognition?
A: Not exactly. A 12-month RCT did not improve the primary memory outcome at its tested dose, but it confirmed safety and suggested signals worth studying at higher doses and with a refined study design (Schwarz et al., 2022). (PMC)
Q: Why is the outlook still positive?
A: Because the mechanism is strong, safety is good, and early signals exist—meaning we’re likely in the “optimize dose and target group” phase of research (Madeo et al., 2018; Wirth et al., 2018; Schwarz et al., 2022). (Science)
Q: Should I do food or supplements?
A: If you can reliably eat spermidine-rich foods, food-first is a great base. Supplements can be useful when consistency is hard—just keep expectations realistic (Muñoz-Esparza et al., 2021; Schwarz et al., 2022). (MDPI)
References
- Kiechl, S., Pechlaner, R., Willeit, P., Notdurfter, M., Paulweber, B., Willeit, K., Werner, P., Ruckenstuhl, C., Iglseder, B., Weger, S., Mairhofer, B., Gartner, M., Kedenko, L., Chmelikova, M., Stekovic, S., Stuppner, H., Oberhollenzer, F., Kroemer, G., Mayr, M., Eisenberg, T., Tilg, H., Madeo, F., & Willeit, J. (2018). Higher spermidine intake is linked to lower mortality: A prospective population-based study. The American Journal of Clinical Nutrition, 108(2), 371–380. https://doi.org/10.1093/ajcn/nqy102 (PubMed)
- Madeo, F., Eisenberg, T., Pietrocola, F., & Kroemer, G. (2018). Spermidine in health and disease. Science, 359(6374), eaan2788. https://doi.org/10.1126/science.aan2788 (PubMed)
- Muñoz-Esparza, N. C., Costa-Catala, J., Comas-Basté, O., Toro-Funes, N., Latorre-Moratalla, M. L., Veciana-Nogués, M. T., & Vidal-Carou, M. C. (2021). Occurrence of polyamines in foods and the influence of cooking processes. Foods, 10(8), 1752. https://doi.org/10.3390/foods10081752 (MDPI)
- Schwarz, C., Stekovic, S., Wirth, M., Benson, G., Royer, P., Sigrist, S. J., Pieber, T. R., Dammbrueck, C., Magnes, C., Eisenberg, T., Pendl, T., Bohlken, J., Köbe, T., et al. (2018). Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline. Aging (Albany NY), 10(1), 19–33. https://doi.org/10.18632/aging.101354 (Aging-US)
- Schwarz, C., Stekovic, S., Wirth, M., Benson, G. S., Royer, P., Sigrist, S. J., Pieber, T. R., Madeo, F., & Eisenberg, T. (2022). Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: A randomized clinical trial. JAMA Network Open, 5(6), e2213875. https://doi.org/10.1001/jamanetworkopen.2022.13875 (PMC)
- Wirth, M., Benson, G., Schwarz, C., Köbe, T., Grittner, U., Schmitz, D., Sigrist, S. J., Bohlken, J., Stekovic, S., Madeo, F., & Flöel, A. (2018). The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial. Cortex, 109, 181–188. https://doi.org/10.1016/j.cortex.2018.09.014 (PubMed)